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Asexual-stage vaccine candidates may be identified by recognition of antibodies to them in the sera of 
naturally immune individuals. Once identified, recombinant molecules expressing the relevant antigen can 
be produced, although such recombinant molecules only seem to be effective at inducing immunity if 
mixed with adjuvant. More information is needed about the role of antibodies in immunity to malaria. In 
an animal model, that of Plasmodium berghei in mice, a fairly effective immune response can be produced 
by inoculating mice with live, proliferating parasites and then keeping the infections subclinical, by drug 
treatment, for 5 weeks. However, the resultant ‘immune1 individuals carry small numbers of parasites 
despite the presence of antibody (premunition). Repeated challenge infections are limited by the hosts’ 
immune responses but sterile immunity is not observed, The immunity that is established only fades in 
the absence of the parasite, In contrast, inoculation with preparations of disrupted parasites, which do not 
seem to contain all the antigenic information of the living parasites, do not lead to an immune response 
which limits parasitaemias. These observations may be the result of antigenic variation. Immunity induced 
in mice by live, attenuated parasites (but not by extracts) protects against challenge with virulent parasites. 
Immunity against the attenuated but not the virulent parasite can be transferred by inoculating naïve mice 
with spleen cells from the immunized mice. The mice given spleen cells can then be protected against the 
virulent parasite by challenge with proliferating, attenuated parasites (but not with extracts). Immune B 
cells from the immune donor and non-immune CD4 cells in the naïve recipient are essential for transfer
of immunity.
A strategy for the development of a vaccine 
against the erythrocytic stages o f  the malarial 
parasite is to look in the serum of a protected 
individual for antibody reactivity against a 
molecule on the surface of the parasite or of a 
parasitized erythrocyte. Such molecules may 
be identified, isolated, expressed in pro- and 
eu-karyotic systems and then used for immu­
nization. Although, usually, the recombinant 
molecules which have been prepared in this 
way only produce a useful immune response if 
inoculated with complete F reund’s adjuvant 
(CFA), it is believed that this strategy will 
eventually result in the development of a mol­
ecular or epitope vaccine. To resolve possible 
problems with antigenic variation or diversity, 
a vaccine cocktail is envisaged. Whether or not 
such an antibody-based vaccine is compatible 
with the characteristics and mechanisms ol
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malarial immunity remains unclear. In fact, 
the mechanisms of malarial immunity are still 
not fully understood.
Although there are differences between ex­
perimental and human malaria, there are par­
allels too. In humans, immunity develops after 
repeated infection and takes years to become 
effective. In animal models, repeated infec­
tions, controlled by chemotherapy, are also 
effective. An easy way to immunize mice 
against Plasmodium berghei, for example, is to 
infect them with the parasite and then keep 
the infections at subclinical levels by adding 
sulphonamide to the rodents1 drinking water
for 5 weeks (Eling and Jerusalem, 1977),
However, live, proliferating parasites must be
(at about one parasite /1 ()5 1 ()7 
erythrocytes) during the whole of the 5-week 
period for effective immunity to develop 
(Kling, 197&/). Repeated injection of dis­
rupted parasites, which supposedly contain
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all the molecules/epitopes of the living para­
sites and which arc regularly used to identify 
antibody reactivity (e.g. by immunoprécipita­
tion), is, in comparison, a poor way to imm u­
nize mice in the absence of CFA (Jerusalem 
and Eling, 1969). Why are live parasites better 
for immunization than disrupted parasites? 
Antigenic diversity in the parasite populations 
used or the generation of antigenic variants 
during their proliferation in vivo could explain 
this puzzle.
Prémunition occurs in murine malaria as in 
human malaria, and so mice ‘im m une5 to P. 
berghei still carry the parasite. Challenge with 
as many as 1Q(J parasites is rapidly suppressed 
to sub pa tent levels by these mice, and re­
peated high-dosc challenges are controlled, 
but the mice eventually become and remain 
carriers of subpatent numbers of the parasite 
(Eling, 1978a, c). This premunition cannot be 
boosted to sterile immunity. Why do parasites 
in low numbers survive despite a fully effec­
tive immune system? If  immunity is antibody 
mediated, why are not all parasites taken out? 
Is antigenic variation the explanation? When 
the parasites present in immune mice are 
given to naïve mice, a normal, virulent infec­
tion develops. The parasites present in ‘im­
mune’ mice therefore appear to be as virulent 
as the original, wild-type parasites used for 
immunization.
Premunition or carrier-immunity is func­
tional; as long as the parasites are present 
there is resistance to re-infection (Eling,
1978a, />, cy 1980; Eling et a l,  1991). If the
parasites disappear spontaneously or are elimi­
nated by radical cure (ehloroquine treatment), 
immunity fades gradually within months, both 
in human and experimental malaria. T he  
longer the parasites are absent, the more 
severe the course o f a challenge infection and 
the more difficult it becomes to control. If  
mice are left long enough without P. berghei, 
the challenge eventually resembles an infec­
tion in untreated controls and all challenged 
mice die. This fading of immunity is pre­
vented if subclinical numbers o f proliferating 
parasites are present or if  such parasites are 
inoculated at regular intervals (e.g. monthly). 
In the latter case, the inoculated parasites
must be viable and proliferating; repeated in­
jection of high numbers (10*) of freeze-thawed 
parasites or of live parasites under ehloroquine 
treatment (to prevent proliferation) fails to 
prevent the immunity fading (Eling, 1978r, 
Eling et a l, 1991). Thus, proliferating para­
sites are important for both the development 
and the maintenance of immunity. We must 
learn to understand why proliferating parasites 
rather than freeze-thawed preparations of 
them are important.
Why are proliferating parasites needed for a 
period of 5 weeks to develop immunity to 
berghei? Infected mice given anti-T-eell 
treatment during the first 2-3 weeks still de­
velop immunity, but if such treatment is given 
later in the 5-week infection it does limit 
development of the immunity, increasing in 
effectiveness the later it is given (Eling, 1979). 
T-cell reactivity, which does not, therefore, 
appear to be an important factor in the first 3 
weeks of the immunization period, was further 
analysed by Celluzzi (1994) and Celluzzi et aL 
(1995). At varying time points during the 
5-week immunization period, as well as after 
the challenge, when the mice had developed 
immunity to the challenge infection, spleen 
cells were transferred to naive recipients. All 
of the recipients developed infections and 
died, indicating that there were parasites 
among the transferred spleen cells and that the 
proliferation of these parasites could not be 
controlled by the recipients. Even transfer of 
all the spleen cells from one immune mouse 
with an established immunity to one recipient 
failed to control the subsequent infection. Re­
peated boosting infections before the transfer 
were ineffective. However, after adding 
sulphonamide to the drinking water of the 
recipients of spleen cells to limit their infec­
tions, it became apparent that transfer of 
spleen cells from mice on or near day 28 of the 
S-week immunization period induced immu­
nity in the recipients in 3 weeks. Surprising!)', 
transfer of peripheral blood from these 'day- 
28' mice also resulted in immunity in
sulphonamide-treated recipients in 3 weeks, ft 
finally became clear that it was the parasites in 
the spleen-cell preparations and in the periph­
eral blood, not the spleen cells themselves,
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that were responsible for the immunization of 
the recipients in a 3-week period. The para­
sites from day-28 mice were therefore isolated, 
cloned, subinoculated by syringe passage into 
splenectomized mice and frozen in liquid N 2. 
These parasites had an attenuated character. 
Whereas the virulent parasites induced cer­
ebral malaria, infections with the attenuated 
parasites developed slowly and, irrespective of 
the number inoculated, never induced cerebral 
malaria. When <  1000 o f these attenuated 
parasites were inoculated, parasitaemias either 
never came up (if <  10 parasites were used) or 
remained at low levels for 3 weeks and then, 
in some of the mice, disappeared. Such mice 
also resisted a subsequent challenge with the 
virulent parasite. (To indicate how surprising 
this was, naïve mice given a single virulent 
parasite each and left untreated all develop 
intense parasitaemias and die.) Infection with 
high numbers o f the attenuated parasite, ob­
tained from passage animals and controlled by 
sulphonamide treatment given in the drinking 
water of the recipients, induced immunity in 3 
weeks, a feature never observed with the viru­
lent parasite.
Recipients of immune spleen cells could not 
control the virulent parasite, whether the viru­
lent parasites were present in the transferred 
spleen-cell preparations or were removed (by 
ehloroquine treatment) from the immune 
donor before collection of the spleen cells and 
given to the recipients after the transfer. 
When immune spleen cells free of virulent 
parasites were transferred, recipients were im­
mune against infection with the attenuated, 
day-28 parasite. Recipients o f  immune spleen 
cells that were infected with the attenuated 
parasite were also immune to the virulent 
parasite when given 1 week after the attenu­
ated parasites. A week-long, subclinical infec­
tion with proliferating, attenuated parasites 
was necessary to develop immunity to the 
virulent parasite; inoculations with freeze- 
thawed attenuated parasites for a week, even 
when given every other dav, failed to induce 
this immunity. Thus, in mice with established 
immunity the virulent parasites persist and are 
controlled, but immune spleen cells only 
transfer immunity to the attenuated parasites
and the attenuated parasites induce immunity 
to the virulent parasites within 1 week. These 
conclusions provided a basic model for further 
transfer studies (Celluzzi, 1994; Celluzzi et al 
1995). Mice with established immunity to the 
virulent parasite received ehloroquine treat­
ment to remove all parasites. Spleen cells from 
them were then transferred to vtu'4
which were immediately infected with the 
attenuated parasite and 7 days later challenged 
with the virulent parasite. Macrophage-deple- 
tion experiments showed that macrophages, 
from the donor or the recipient, were not 
necessary for successful immunization by 
transfer of immune spleen cells. However, 
B-cells had to be present among the trans­
ferred immune spleen cells for development of 
immunity in the recipients. CD4 cells also had 
to be present but, surprisingly, not necessarily 
in the transferred immune spleen cells. When 
CDS cells were depleted in the recipients 
(CD4 cells present), transferred immune
spleen cells depleted of CD4 cells provided 
immunity to the attenuated and (7 days later) 
to the virulent parasites. In mice with estab­
lished immunity to the virulent parasite, CD4 
depletion resulted in loss of immunity to the 
virulent parasite.
What about fading o f immunity and the
capacity to transfer immunity using spleen 
cells? When mice with established immunity 
against both attenuated and the virulent para­
sites were radically cured by ehloroquine 
treatment, they lost immunity to the virulent 
parasite after 3 -4  months. After 6 months, 
however, they were still immune to the atten­
uated parasite and immunity to the virulent 
parasites developed when the virulent para­
sites were given 7 days after the attenuated 
parasite. Immune donors lost their capacity to 
transfer immunity via their spleen cells after 
being pa rasile-free for approximately 2 
months. When recipients received parasite- 
free immune spleen cells only and infection, 
with the attenuated parasites followed, 7 days 
later, by the virulent parasite, was delayed, 
their capacity to develop immunity was 
lost after a delay of 4 months. Could this 
mean that; immunity to the attenuated parasite 
is dependent on the presence of immune
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B cells and that (non-immune) C D 4 cells are 
necessary for the development o f  immunity 
against the virulent parasite? What is the dif­
ference between the attenuated and the viru­
lent parasite, and why do we need live, 
proliferating parasites for development of the 
immune reactions? Do attenuated and virulent 
parasites differ in their repertoires o f  antigenic 
variants. Does the attenuated parasite simply
lack an antigen that induces pathology? 
Further study of the attenuated parasite 
should be useful in the development of a 
malaria vaccine. We need to know whether 
similar attenuated parasites can develop in P. 
falciparum-human interactions and whether 
the mechanisms observed in the mouse model 
also operate in human immunity.
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